Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Dr Andrew A. Parsons

Dr Andrew A. Parsons

Director of Reciprocal Minds Limited & Chairman of Pharmasum Therapeutics AS

Connect with Dr Andrew A. Parsons on LinkedIn
Website:

About the author:

Dr Andrew A Parsons initially trained as a Pharmacologist and Neuroscientist and has over 90 peer reviewed publications, several patents and contributed to Educational Books in Science and Medicine. His former scientific focus was in areas of neuroplasticity and neurodegeneration. He played key roles on individual projects from initial idea through development and the market place. Working across traditional organisational and cultural boundaries he was instrumental in creating External Innovation platforms within a large Pharma company. Through this he became interested the impact of Human Factors on operational processes. He is a member of the Pharmaceutical Special Interest group and an associate member of the Chartered Institute of Ergonomics and Human Factors.

He is the Director of Reciprocal Minds Limited which supports individuals and groups undergoing personal and professional development and challenges to health and wellbeing. He is the co-author of “Leading with Presence, what it is, why it matters and how to get it?” He is also the Chairman of Pharmasum Therapeutics AS, an early stage Biotech company.


Posts by Dr Andrew A. Parsons

Disrupting innovation: From geography, penguins and ocean currents to diagnosing disease by its smell

Posted on November 15th, 2017 in Pharma R&D

banner-1235602_640

How to become aware of what I don’t know? These insights can stimulate disruption. They help us see a whole new world or perhaps a pattern of activities that need to change. As Donald Rumsfeld described, it is those things we don’t know we don’t know that can be issues for the future. They can also be lost opportunities in scientific understanding and commercial success. Continue reading “Disrupting innovation: From geography, penguins and ocean currents to diagnosing disease by its smell” »

Considering lifestyle and environment to maximize the economic value of R&D

Posted on November 10th, 2017 in Pharma R&D

With an interest in systems approaches, I am always on the look-out for interesting papers in this area. A recent paper in Drug Discovery Today caught my eye for several reasons (1). The first was the extent of the problem with non-alcoholic liver disease. Continue reading “Considering lifestyle and environment to maximize the economic value of R&D” »

Snakes (aka Chutes) and Ladders – failures and opportunities

Posted on October 13th, 2017 in Pharma R&D

If there ever was a children’s game that would help prepare the next generation of pharmaceutical R&D scientists and researchers, it would be Snakes and Ladders (Chutes and Ladders in the US). Continue reading “Snakes (aka Chutes) and Ladders – failures and opportunities” »

From mega-merger to big bang?

Posted on October 3rd, 2017 in Pharma R&D

It was not so long ago that there was a perception that the biopharma industry was consolidating and becoming leaner and more focused in its operations, moving to a regional hotspot model Continue reading “From mega-merger to big bang?” »

  1. 1
  2. 2
  3. 3
  4. 7